Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Myelofibrosis; Polycythaemia vera; Thrombocytosis
  • Focus Registrational; Therapeutic Use
  • Acronyms COMFORT-I
  • Sponsors Incyte Corporation

    • Most Recent Events

    • 15 Jun 2023 Results of post-hoc analysis of two studies COMFORT-1 & COMFORT-II assessing the impact of new or worsening anemia induced by ruxolitinib treatment on spleen volume response and total symptom score in patients with myelofibrosis, presented at the 28th Congress of the European Haematology Association.
    • 25 Feb 2023 Results of post hoc, pooled analysis of COMFORT-I and COMFORT-II examining relevant disease outcomes based on the disease duration before ruxolitinib initiation, published in the Cancer
    • 17 Jun 2022 Results assessing MAICs conducted to correct for potential imbalances in baseline characteristics, comparing the primary endpoint SVR35 and secondary endpoint TSS50 at Week 24 for the combination of pelabresib and ruxo (MANIFEST Arm 3) with Phase 3 ruxo monotherapy (COMFORT-I and II, SIMPLIFY-1) and fedratinib monotherapy (JAKARTA) data, presented at the 27th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top